Healthcare mergers and acquisitions in Canada are entering a more complex and strategically driven phase, as rising deal values, artificial intelligence and global competition for life sciences assets reshape transaction strategy across the sector.
While overall deal volumes have remained relatively steady – consistent with PwC Canada's 2026 M&A market outlook, which projects Canadian transaction volume holding steady through the first half of 2026 – lawyers say the defining feature of current activity is the increasing scale and sophistication of transactions, particularly in pharmaceuticals, biotechnology and healthcare technology. At the same time, healthcare services remain active, supported by consolidation trends and demographic demand pressures.
Across subsectors, healthcare M&A is increasingly defined less by volume and more by targeted acquisitions of innovation, data-driven capability and scalable platforms that can support long-term growth in an environment where regulatory scrutiny and valuation discipline are both intensifying.
Canadian healthcare M&A enters a new phase
Susan Newell, partner with Osler, Hoskin & Harcourt LLP in Toronto, says the Canadian healthcare M&A market remains active across a wide range of subsectors, including healthcare service providers, virtual care, pharmaceuticals, medical devices and emerging health technology companies. While some traditional rollup strategies have matured, she says transaction activity remains resilient, particularly as innovation in medtech and digital health continues to generate new acquisition targets.
Several structural forces are driving deal flow, including ongoing consolidation among healthcare providers as owners approach retirement or succession planning, sustained investor appetite for healthcare innovation, and long-term demographic pressures linked to Canada’s aging population and rising demand for care. According to the Canadian Institute for Health Information's 2025 national health expenditure trends report, total Canadian healthcare spending is projected to reach $399 billion in 2025, growing at 4.2 percent – outpacing overall economic growth – a scale of sector activity that reinforces its long-term appeal to acquirers.
“There is no single buyer profile,” Newell says. “Private equity remains active, but strategic buyers are increasingly pursuing vertical integration opportunities. Foreign healthcare operators are also entering the Canadian market.”
She adds that buyers are increasingly focused on building integrated care models designed to deliver more seamless patient experiences, often combining service delivery with digital tools and data-driven infrastructure. In this environment, healthcare transactions are increasingly shaped by system-level integration rather than standalone asset acquisition strategies.
Newell also notes that healthcare transactions now require a more nuanced assessment of regulatory exposure at the outset of a deal. Because healthcare assets are often tied to licensing regimes, privacy obligations and professional oversight frameworks, even small compliance issues can have material implications for valuation and deal structure. As a result, regulatory diligence is increasingly embedded in commercial negotiations, shaping deal feasibility, representations and warranties, indemnities, closing conditions, and purchase price adjustments, rather than being treated as a late-stage legal review.
Cross-border buyers reshape the market
Laurie Turner, leader of the health law group at Fasken Martineau DuMoulin LLP in Toronto, says another emerging trend is growing interest from international healthcare companies looking to establish a Canadian presence through acquisitions, particularly in virtual care.
She says buyers from the United States and the United Kingdom are increasingly targeting Canadian companies that have built scalable virtual healthcare platforms, reflecting the lasting impact of changes in healthcare delivery that accelerated during the COVID-19 pandemic.
"We've seen a significant increase in transactions involving American and UK companies seeking entry into the Canadian healthcare market," she says.
Turner says much of that interest is being driven by consumer demand for convenient access to care. Virtual platforms allow patients to consult with a healthcare provider, receive a prescription and have medication delivered to their homes, often much more quickly than through traditional primary care channels.
Although Canada's publicly funded healthcare system has historically limited opportunities for private healthcare businesses, she says evolving delivery models have created commercially attractive niches, particularly where services can be provided outside the traditional publicly insured framework.
Turner notes that the sector also illustrates the unique regulatory challenges that distinguish healthcare transactions from deals in many other industries.
"These transactions require structures that comply with healthcare regulations while still allowing investors to participate in the economics of the business," she says.
That makes healthcare lawyers central to transaction planning from the outset, she adds, as legal teams work alongside corporate advisers to develop compliant ownership and management structures before negotiations move into the later stages of a deal.
Life sciences drive deal value
John Emanoilidis, co-head of the M&A practice at the Toronto office of Torys LLP, notes that healthcare M&A in Canada has seen a marked increase in deal value, even as overall transaction volume remains relatively stable. He notes that total deal value increased significantly from approximately $4.5 billion in 2023 to more than $12 billion in 2025, driven primarily by larger pharmaceutical and biotechnology transactions.
“What changed was the size of transactions,” he says. “Biotech and pharmaceutical transactions are leading by deal value, while healthcare facilities and services account for the greatest number of deals.”
He adds that pharmaceutical dealmaking continues to be shaped by urgency, as companies respond to looming patent expiries and the resulting risk of significant revenue erosion.
“Pharma M&A is fundamentally driven by innovation and urgency,” Emanoilidis says. “Companies are facing significant revenue exposure from patent expiries and are looking to acquire revenue-generating or near-commercial assets.”
This dynamic continues to fuel global competition for high-value assets, particularly in therapeutic areas where clinical pipelines are limited and development timelines are long. He notes that buyers are increasingly relying on structured bidding processes and disciplined valuation frameworks to navigate competitive biotech auctions.
Teresa Reguly, co-leader of the intellectual property and food and drug regulatory practices at Torys LLP in Toronto, says the so-called patent cliff remains a central driver of healthcare M&A activity, although the nature of pharmaceutical innovation has evolved significantly. She notes that today’s therapies increasingly involve biologics, precision medicines, and highly specialized treatments, which require greater investment and longer development timelines.
“These products take longer to develop, require more investment, and often reach the market with less remaining patent life,” she says.
As a result, competition for high-quality assets has intensified, particularly in areas such as oncology and obesity treatments, including GLP-1 therapies, where strategic interest from global pharmaceutical buyers remains strong.
Reguly says the result is a more selective market where fewer assets are available, but those that do come to market often attract significant attention and premium valuations. She adds that this has elevated the importance of early-stage intellectual property and regulatory diligence, particularly around exclusivity timelines and data protection frameworks.
Canada’s innovation pipeline attracts buyers
Kyle Misewich, a corporate and M&A partner at Blake Cassels & Graydon LLP in Vancouver, says Canada continues to play an important role in global healthcare M&A, particularly as a consistent source of high-quality biotechnology and life sciences innovation that attracts cross-border capital.
He emphasizes that Canada’s healthcare ecosystem has developed a strong reputation for producing companies that are both scientifically advanced and commercially relevant, making them attractive acquisition targets for global pharmaceutical and strategic buyers.
“We’re also seeing increased competition from US and European buyers for Canadian assets, particularly in areas where clinical-stage companies can plug directly into global development pipelines.”
Misewich adds that Canadian biotech assets increasingly include clinical-stage companies and platform technologies that integrate into global pharmaceutical pipelines, particularly in precision medicine, specialty therapeutics and next-generation biologics.
He also highlights the continued expansion of healthcare technology and digital health as a distinct investment category within Canadian healthcare M&A. This includes virtual care platforms, remote diagnostics, patient monitoring systems and workflow automation tools that are increasingly embedded into healthcare delivery infrastructure.
He says these assets are increasingly evaluated not as standalone software businesses but as infrastructure components of healthcare systems, particularly as providers and payors seek efficiency gains, interoperability and improved patient outcomes.
Healthcare services remain disciplined
Nick Pasquino, partner and co-leader of the healthcare group in Toronto at Borden Ladner Gervais LLP, says healthcare services remain a steady but increasingly disciplined source of M&A activity. He notes that while private equity remains highly active in fragmented healthcare markets, earlier consolidation waves have matured, resulting in fewer high-growth rollup opportunities.
“Many of the large consolidators have already achieved significant scale,” he says. “Those markets are more mature today than they were a decade ago.”
Pasquino also points out that valuation discipline has returned to healthcare services, with buyers placing greater emphasis on sustainable margins rather than aggressive expansion assumptions. This has led to more conservative structures and greater use of deferred consideration in certain transactions.
Claire Gowdy, a partner at Fasken Martineau DuMoulin LLP in Toronto, says activity in healthcare services has picked up after a relatively subdued period in 2025, although buyers remain disciplined on pricing and transaction structures.
"Toward the end of last year, we started to see activity return, and that has continued into 2026," she says. "It's still cautious, but we're seeing deals happen because the gap between buyer and seller expectations has narrowed."
Gowdy says much of the current activity remains centred on expanding existing healthcare platforms rather than launching entirely new consolidation strategies. Buyers are focusing on acquisitions that fill geographic gaps, broaden service offerings or strengthen established networks in sectors such as dentistry, veterinary medicine and diagnostic imaging. That subsector-level pattern is tracked in MNP Corporate Finance's Q1 2026 Canadian healthcare services M&A quarterly update, which documents continued deal activity across dental, homecare, pharmaceutical, and digital health platforms through the first quarter of 2026.
Even in mature consolidation markets, Gowdy says succession planning continues to create opportunities as retiring healthcare professionals seek to monetize their practices while maintaining regulatory compliance through carefully structured ownership arrangements.
AI transforms transaction strategy
Artificial intelligence has become one of the most significant and complex forces shaping healthcare M&A across subsectors. BLG’s Pasquino says AI is now widely embedded across healthcare operations, but its valuation remains difficult to assess given how quickly its use is evolving.
“The challenge is determining how to value AI-enabled businesses compared to those that are not leveraging AI technology,” he says.
As a result, deal structures increasingly rely on earnouts and contingent consideration mechanisms tied to performance milestones, particularly where AI-driven efficiencies or revenue gains are still emerging.
Torys’ Emanoilidis says AI is rarely assessed in isolation in healthcare transactions. Instead, buyers focus on the interaction among AI capabilities, proprietary datasets, and commercial applications.
“The real value comes from the combination of AI, data and commercial application,” he says. “Buyers want to know whether the technology can improve outcomes, create efficiencies or generate new revenue streams.”
He adds that the most attractive opportunities are those where AI is already embedded into validated clinical or operational workflows, rather than early-stage experimental tools.
Reguly at Torys says AI has also shifted intellectual property analysis in healthcare transactions. While patents remain relevant, she says buyers are increasingly focused on data rights, consent frameworks and governance structures underpinning AI systems.
“The key question is whether the company has access to a proprietary, legally compliant dataset that can support the technology,” she says.
Fasken’s Gowdy notes AI itself is rarely treated as a standalone source of value in healthcare transactions. Instead, buyers evaluate whether a company's use of AI strengthens its overall growth prospects through digital transformation and operational capability.
"We're not seeing companies acquired simply because they have AI," she says. "It's one factor that's considered in evaluating the overall strength and future potential of the business."
That has expanded the scope of legal due diligence. Gowdy says transaction teams increasingly include healthcare, intellectual property, information technology and cybersecurity specialists who assess where data is stored, whether AI systems comply with privacy requirements and whether cybersecurity or governance issues could affect post-closing risk.
The road ahead
Lawyers working in this area of practice emphasize that healthcare M&A requires a highly multidisciplinary approach. Emanoilidis says corporate counsel must coordinate with regulatory, intellectual property, privacy and technology specialists to assess transaction risk properly.
“Together, they assess compliance risks, data governance frameworks, ownership issues and regulatory requirements,” he says.
Looking ahead, lawyers expect healthcare M&A in Canada to remain active, with continued emphasis on innovation, scale and data-driven value creation. Pharmaceutical and biotechnology transactions are likely to remain driven by patent expiries and pipeline pressure, while healthcare technology and AI-enabled solutions continue to attract strong investor interest.
At the same time, increasing regulatory complexity, data governance requirements and valuation challenges suggest a more selective deal environment in which execution risk is becoming as important as strategic fit.
In this evolving market, success will depend not only on identifying opportunities but also on navigating the legal, regulatory, and technological complexity that now defines healthcare transactions in Canada.